A
Arctic Therapeutics
Transforming drug discovery and development by harnessing the power of applied of genomics
About Arctic Therapeutics
AT is a drug discovery and development company, focused on identifying the genetic underpinnings of rare and common diseases. The company uses bioinformatic approaches and AI to eliminate significant risks associated with traditional drug development as well as sharply reducing the enormous cost associated with traditional drug discovery and development. The company is advancing to frontrunners further into the clinic - AT-001 for the treatment of rare and common forms of dementia, and AT-004 for inflammatory skin diseases, ranging from acne vulgaris and atopic dermatitis. Keywords: Healthcare Devices, Services, Supplies, Drug Development, Drug Discovery, Drug Discovery Firm, Drug Discovery Tech, Genealogical Database, Genetic Testing, Novel Therapies, Novel Therapies Development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Reykjavík, Iceland
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 76.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Core AI, Genome Engineering
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Deep Learning
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2025 | $29M | $117M | Kerecis · EIC Fund · Kaldbakur · Sanos Group | ↗ |
| GRANT✓Other financing | Oct 2022 | $2.5M | — | European Innovation Council | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Arctic Therapeutics is 1.4K monthly website visits, down 12.5% over the last three months. Arctic Therapeutics's team declined 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A6 investors entered at this stage
EIC Fund
Kerecis
Kaldbakur
Sanos Group
ChemoMetec
Cerebrum DAO
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arctic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arctic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.